A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Key facts
- Where
- Boston, Cutler Bay, Fremont, Northridge, Portsmouth, San Antonio, Santa Clarita, South Jordan, and Troy, United StatesSee the 9 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07533006, who can take part
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Arash Mostaghimi (principal investigator)Taking people
- Health Clinical Research, LLCCutler Bay, United StatesContact: Soroush Aghigh (principal investigator)Taking people
- Center For Dermatology Clinical Research, Inc.Fremont, United StatesContact: Sunil Dhawan (principal investigator)Taking people
- Northridge Clinical TrialsNorthridge, United StatesContact: Navid Ezra (principal investigator)Taking people
- StracskinPortsmouth, United StatesContact: Abel Jarell (principal investigator)Taking people
- Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels AvenueSan Antonio, United StatesContact: John Browning (principal investigator)Taking people
- Cura Clinical Research - Santa Clarita - Kelly Johnson ParkwaySanta Clarita, United StatesContact: Bernard Raskin (principal investigator)Taking people
- Jordan Valley Dermatology & Research CenterSouth Jordan, United StatesContact: Douglass Forsha (principal investigator)Taking people
- Revival Research Institute, LLCTroy, United StatesContact: Ali Moiin (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07533006EU 2025-524727-41-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.Read full original descriptionShow less
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study drug will be administered intravenously (IV) (into a vein in the arm).
The study will last approximately 48 weeks, including screening.
Inclusion: Have severe Alopecia Areata (AA) that meets all of the following criteria:; Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score; The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years; No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months; Agree not to use any AA treatments during the study.
Exclusion: Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study; Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study; Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness; Primarily "diffuse" type of AA (characterized by diffuse hair shedding); Are currently experiencing other forms of alopecia.